Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 28;12:732826. doi: 10.3389/fimmu.2021.732826

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Luo, Zhu, Chen, Shui and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Overview of immune reconstitution to cytomegalovirus and cellular immunotherapy after three major approaches of haploidentical stem cell transplantation (haploSCT). In vivo TCD-haploSCT, in vivo T-cell depletion (TCD) using antithymocyte globulin for haploSCT; Ex vivo TCD-haploSCT, ex vivo TCD using CD34 + positive selection for haploSCT; PTCy-haploSCT, T-cell replete haploSCT using posttransplant cyclophosphamide. G-CSF, granulocyte-colony stimulating factor; G-PBSC, G-CSF primed peripheral blood stem cells; G-BM, G-CSF primed bone marrow; HSC, hematopoietic stem cell; CMV, cytomegalovirus; CNI, calcineurin inhibitors; MTX, methotrexate; MMF, mycophenolate mofetil; DLI, donor lymphocyte infusion; NK cell, natural killer cell; Treg, regulatory T cell; HSCT, hematopoietic stem cell transplantation. Created with BioRender (https://biorender.com/).